Protein

Haploinsufficient tumor suppressor Tip60 negatively regulates oncogenic Aurora B kinase

12 days ago   |   By Journal of Biosciences

Abstract
The Aurora kinases represent a group of serine/threonine kinases which are crucial regulators of mitosis. Dysregulated Aurora kinase B expression, stemming from genomic amplification, increased gene transcription or overexpression of its allosteric activators, is capable of initiating and sustaining malignant phenotypes. Although AurkB level in cells is well-orchestrated, studies that relate to its stability or activity, independent of mitosis, are lacking. We report that AurkB undergoes acetylation in vitro by lysine acetyltransferases belonging to different families, namely by...
Read more ...

 


Search by Tags

   Protein      Genome      Cancer      Gene      Genomics      Genes  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Cover Image, Volume 87, Issue 12

Cover Image, Volume 87, Issue 12

Reverse Cover: The cover image is based on the Review Critical assessment of methods of protein structure prediction ‐Round XIII by Andriy Kryshtafovych, Torsten Schwede, Maya... Read more ...

With “Inflection Year” Ahead, Ovid Adds Novartis's Tardio to C-Suite

With “Inflection Year” Ahead, Ovid Adds Novartis's Tardio to C-Suite

About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases. Now, with the completion... Read more ...

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged... Read more ...

Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin

Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin

Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company's new approach to treating brain disorders has proven attractive enough... Read more ...

Yelick Recognized for Outstanding Leadership in HPC

Yelick Recognized for Outstanding Leadership in HPC

Katherine Yelick has been honored by HPCwire as their Editor's Choice for Outstanding Leadership in high-performance computing. (Photo courtesy of Berkeley Lab Computing... Read more ...

Patient Storytelling: There's an Art to it!

Patient Storytelling: There's an Art to it!

After 30-plus years working in Washington DC, it's clear healthcare decision makers recognize that a patient's story can add value to a discussion when data cannot. While the... Read more ...

Correction to: Investigating the parameter space of evolutionary algorithms

Following publication of the original article , an error was reported in one of the experiments. Read more ...

Myovant's oral prostate cancer drug matches incumbent in phase 3

A phase 3 trial of Myovant Sciences' relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval next year. Read more ...

Novartis tight-lipped on MedCo buyout rumors

The Medicines Company, fresh from its turn at the American Heart Association this weekend, has seen its shares jump on growing rumors that Swiss major Novartis may be... Read more ...

Novo Ventures, Broad Institute form drug discovery pact

Novo Ventures has joined with the Broad Institute to support drug discovery projects. The partners will use $25 million in Novo Ventures' money to fund drug discovery projects... Read more ...